Lectin-type oxidized LDL receptor-1 as a potential therapeutic target for cerebral cavernous malformations treatment
LOX-1 is involved with pathways implicated in CCM pathogenesis and our data here reveals that LOX-1 expression is significantly elevated in CCM patients as compared to matched healthy control individuals, including both source tissue from surgically excised CCMs and in analysis of samples collected from outside of the central nervous system, particularly urine. This proof-of-principle data suggests that LOX-1 may have potential utility as a target for CCM treatment and supports further investigation related to its potential mechanistic impact on CCM pathogenesis.
Authors
- Tyra Martinez
- Sana Nasim (ORCID: https://orcid.org/0000-0002-1110-4513)
- Julie Sesen (ORCID: https://orcid.org/0000-0002-1819-6430)
- Karthik Ashok
- Aram Ghalali
- Edward R. Smith (ORCID: https://orcid.org/0000-0002-6317-8450)
- Alexander M. Tucker
- Gregory G. Heuer (ORCID: https://orcid.org/0000-0002-1989-0141)
- Miguel Alejandro Lopez‐Ramirez (ORCID: https://orcid.org/0000-0001-7089-4060)
- Shih-Shan Lang
Institutions
- Boston Children's Hospital (US)
- Children's Hospital of Philadelphia (US)
- Harvard University (US)
- University of California San Diego (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Frontiers in Neuroscience
- Published
- 2024-08-21
- DOI
- https://doi.org/10.3389/fnins.2024.1442110
- Citations
- 2
- Primary Topic
- Vascular Malformations Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.74